Alluvi, previously BI 4744, presents a significant advance in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling effectiveness https://alluvi-peptides545066.mywikiparty.com/user